Volume | 5,048,178 |
|
|||||
News | (3) | ||||||
Day High | 2.64 | Low High |
|||||
Day Low | 2.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.26 | 2.10 | 2.64 | 2.16 | 2.00 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
25,312 | 5,048,178 | $ 2.30 | $ 11,603,029 | - | 1.85 - 44.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:25 | 83 | $ 2.1897 | USD |
Bio Path Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.46M | 678.80k | - | 0 | -16.08M | -23.69 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bio Path News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.83 | 2.83 | 1.91 | 2.25 | 101,026 | -0.65 | -22.97% |
1 Month | 2.31 | 4.55 | 1.85 | 3.21 | 3,186,437 | -0.13 | -5.63% |
3 Months | 4.30 | 7.6699 | 1.85 | 3.76 | 2,590,023 | -2.12 | -49.30% |
6 Months | 11.00 | 12.00 | 1.85 | 3.97 | 1,255,136 | -8.82 | -80.18% |
1 Year | 32.80 | 44.80 | 1.85 | 9.27 | 1,393,486 | -30.62 | -93.35% |
3 Years | 137.00 | 172.398 | 1.85 | 33.79 | 600,420 | -134.82 | -98.41% |
5 Years | 287.20 | 486.80 | 1.85 | 83.27 | 570,971 | -285.02 | -99.24% |
Bio Path Description
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. |